Everything below concerns Translational gap. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2025-11-28. Numbers and descriptions here follow the published literature rather than marketing material.
Dihexa is not approved for human use in the United States or the European Union. It is commonly sold as a research chemical, a category that may not require the same regulatory review as medicines. Buyers should note that product labels may lack independent verification of identity or purity. The legal status can vary by country, and importation may be restricted. Reliable information about sourcing and quality is often scarce. Scientific publications typically use synthesized material from laboratories rather than commercial consumer products.
Dihexa is a synthetic peptide studied in laboratory research. It is often described as an angiotensin IV analog or a hepatocyte growth factor mimetic. The compound emerged from investigations into angiotensin IV and its effects on neural pathways. It is not an approved medication, and controlled human trials are lacking. In literature and online forums, it is discussed mainly as a research chemical. Its chemical name appears as N-hexanoic-Tyr-Ile-(6-aminohexanoic amide) in some sources.
Development of dihexa has been linked to academic research on synaptogenesis, the formation of new synapses. Preclinical studies in rodents have examined its effects on learning and memory tasks. These studies are often cited in discussions about cognitive enhancement, but they do not establish safety or efficacy in humans. The compound's patent and commercial history is limited, and it is not widely available through pharmaceutical channels. Most information comes from animal models and in vitro experiments. Researchers continue to explore its basic biology rather than clinical applications.
Dihexa is not approved as a medicine in major regulatory jurisdictions. It is commonly sold as a research chemical for laboratory use, though such products may not be standardized or independently verified. Scientific literature on dihexa includes in vitro assays, rodent studies, and reviews that discuss its proposed mechanism. The distinction between peer-reviewed findings and commercial promotion is important when evaluating available information. Open questions include its precise binding interactions, pharmacokinetics, and whether animal results translate to human biology.
Dihexa is a synthetic peptide derived from angiotensin IV, a naturally occurring fragment of the renin-angiotensin system. Researchers modified the angiotensin IV structure to improve metabolic stability and central nervous system activity. It is frequently described as a hepatocyte growth factor mimetic because it can activate the c-Met receptor pathway in experimental systems. Its development reflects interest in small peptides that influence synaptic plasticity and cognitive processes. Most information comes from preclinical studies rather than controlled human trials.
| Property | Value | Notes |
|---|---|---|
| CAS Registry Number | 1401708-83-5 | Identifier used in chemical databases. |
| Common synonyms | P21; N-hexanoic-Tyr-Ile-(6-aminohexanoic amide) | Names vary by supplier and publication. |
| Physical form | White to off-white powder | Lyophilized solid typical of peptides. |
| Solubility | Soluble in DMSO; limited in water | Aqueous preparation may need a co-solvent. |
| Storage | -20 °C, desiccated, protected from light | Reduce freeze-thaw cycles to maintain stability. |
Chemically, dihexa belongs to a broader group of angiotensin IV analogs. Researchers have modified the natural peptide to alter stability, binding, or distribution. Such changes can affect how the molecule behaves in experiments. The parent peptide angiotensin IV is involved in various physiological processes, but the modified analog is not identical to it. Public summaries sometimes blur the distinction between the natural fragment and the synthetic research compound. This distinction matters when interpreting study results.
Dihexa is a synthetic peptide that has been examined in laboratory and animal research. Its design is based on angiotensin IV, a naturally occurring peptide fragment produced in the body. The short name dihexa appears in scientific papers and online discussions, while the full chemical name describes a modified peptide chain. It is not a vitamin, mineral, or plant-derived compound. Suppliers typically present it as a research chemical rather than an approved medicine.
The full name often given is N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide. This name indicates a chain containing tyrosine, isoleucine, and a six-carbon amino acid derivative. Databases list a CAS Registry Number and a molecular formula for the compound. The peptide is small compared with proteins, and its structure allows it to be studied in cell cultures and animal models. Exact identity depends on the supplier's synthesis and purification process. Minor impurities can remain after synthesis.
Human safety data are sparse. No widely accepted dosing regimen, long-term safety profile, or clinical efficacy endpoint has been established. Published animal results can suggest directions for further study, but species differences and study design limit direct translation. Open questions include bioavailability, blood-brain barrier penetration, metabolism, and whether observed effects arise from a single target or multiple pathways. Replication across independent laboratories remains an important benchmark for evaluating the strength of preclinical claims.
Most published reports on dihexa come from cell cultures and animal models. Studies have examined markers of synapse formation, dendritic spine density, and performance on learning tasks in rodents. Proposed mechanisms center on hepatocyte growth factor and its c-Met receptor, with additional attention to angiotensin IV-related pathways. These findings are experimental and have not been confirmed as clinical benefits in humans. The literature often uses different tasks and endpoints, which complicates direct comparison across studies.
Regulatory status differs by country, but dihexa is generally not approved as a therapeutic product. It is often sold as a research chemical, which means purity, labeling, and handling fall outside pharmaceutical drug standards. Some jurisdictions restrict the sale of peptides intended for human consumption. Researchers and suppliers may therefore face different legal requirements depending on location. Import rules and customs enforcement can also affect how such compounds move across borders.
=== Storage of potatoes === Various storage conditions can have an impact on the level of solanine in potatoes. Glycoalkaloid levels increase when potatoes are exposed to light because light increases synthesis of glycoalkaloids like solanine. Potatoes stored in a dark place avoid increased solanine synthesis. Potatoes that have turned green due to increased chlorophyll and photosynthesis are indicative of increased light exposure and are therefore associated with high levels of solanine. Synthesis of solanine is also stimulated by mechanical injury because glycoalkaloids are synthesized at cut surfaces of potatoes. Storage of potatoes for extended periods of time has also been associated with increased solanine content. A study found that the solanine levels in Kufri Jyoti and Kufri Giriraj potatoes increase solanine levels by 0.232 mg/g and 0.252 mg/g respectively after being poorly stored in a heap.
== History == In 1976, the first Old Chicago taphouse opened in Boulder, Colorado. The first Gordon Biersch Brewery Restaurant was opened in Palo Alto, California on July 6, 1988. The first Rock Bottom restaurant opened in Denver, Colorado in 1991. In 1993, Big River Breweries opened its first location in Chattanooga, Tennessee. Rock Bottom Restaurants, Inc., made an initial public offering in 1994. In 1995, the first ChopHouse opened in Denver, Colorado. Big River Breweries opened the only brewpub at Walt Disney World in 1996. A private management buyout took Rock Bottom Restaurants, Inc. private in 1999. In the same year, Gordon Biersch was acquired by Big River Breweries. In 2000, Rock Bottom Restaurants formed the Rock Bottom Foundation, a 501(c)(3) non-profit entity. Rock Bottom Restaurants laid off about 20% of its corporate staff in 2007 and slowed its growth plans along with ceasing its search for an equity partner. In 2010, Rock Bottom Restaurants and Gordon Biersch Brewery Restaurant Group were acquired by Centerbridge Capital Partners and merged to form CraftWorks Restaurants and Breweries, Inc. On November 1, 2018, CraftWorks announced that it had acquired Logan's Roadhouse and formed Craftworks Holdings. Logan's Roadhouse is a chain of restaurants founded in 1991 in Lexington, Kentucky. The chain's menu includes mesquite-grilled steaks, traditional American fare (sandwiches, soup, salads, and seafood), ice-cold longneck beer, and homemade yeast rolls. On June 12, 2020, Craftworks was purchased by SPB Hospitality for $93 million.
Kutlu Özergin Ülgen is a Turkish biochemical engineer researching pharmacophore modelling to identify pharmacological chaperones used to treat infectious diseases, genetic diseases, and cancer. Ülgen is a professor in the department of chemical engineering at Boğaziçi University.
== Treatment == There has been too little experience on the treatment of LECT2 amyloidosis to establish recommendations other than offering methods to support kidney function and dialysis. Nonetheless, it is important to accurately diagnose ALECT2-based amyloid disease in order to avoid treatment for other forms of amyloidosis.
=== Mechanism of action === Ezetimibe inhibits the absorption of cholesterol from the small intestine and decreases the amount of cholesterol normally available to liver cells. The lower levels of cholesterol in the liver cells lead them to absorb more cholesterol from circulation thus lowering the levels of circulating cholesterol. It blocks the critical mediator of cholesterol absorption, the Niemann-Pick C1-like 1 (NPC1L1) protein on the gastrointestinal tract epithelial cells, as well as in hepatocytes; it blocks aminopeptidase N and interrupts a caveolin 1–annexin A2 complex involved in trafficking cholesterol.
Sources: en.wikipedia.org
== Interactions == Drug interactions with drotrecogin have not been systematically studied in patients with severe sepsis. Caution should be exercised when using other drugs that affect hemostasis concomitantly with drotrecogin (e.g. aspirin, warfarin, clopidogrel). However, the use of low dose prophylactic Heparin did not affect safety when given concurrently with drotrecogin.
=== Season 2 === Season 2 opens with Radhi adjusting to life outside the hospital after stepping away from her duties, while Reena struggles under the new leadership of Arjun, the recently appointed CEO. Encouraged by her children and her own sense of purpose, Radhi reclaims her role. The story follows Radhi and Reena dealing with their past, fuelled by the arrival of Reena's biological father and Radhi's past love interest, Dr. Vijay. Soon, both Reena and Vijay get to know the truth about each other but very soon the former meets with an accident.
== Creation and yield == The fissile isotope uranium-235 fuels most nuclear reactors. When 235U absorbs a thermal neutron, one of two processes can occur. About 85.5% of the time, it will fission; about 14.5% of the time, it will not fission, instead emitting gamma radiation and yielding 236U. Thus, the yield of 236U per 235U+n reaction is about 14.5%, and the yield of fission products is about 85.5%. In comparison, the yields of the most abundant individual fission products like caesium-137, strontium-90, and technetium-99 are between 6% and 7%, and the combined yield of medium-lived (10 years and up) and long-lived fission products is about 32%, or a few percent less as some are transmuted by neutron capture. The second-most used fissile isotope plutonium-239 can similarly fission or not on absorbing a thermal neutron, the latter giving plutonium-240, a major component of reactor-grade plutonium (plutonium recycled from spent fuel that was originally made with enriched natural uranium and then used once in an LWR). 240Pu decays with a half-life of 6561 years into 236U. In a closed nuclear fuel cycle, most 240Pu will fission (possibly after more than one neutron capture) before it decays, but 240Pu discarded as nuclear waste will decay over thousands of years. As 240Pu has a shorter half-life than 239Pu, the grade of any sample of plutonium mostly composed of those two isotopes will slowly increase, while the total amount of plutonium in the sample will slowly decrease over centuries and millennia.
Arafat Jamal, the UNHCR Representative in Afghanistan, noted that they faced limited options amid the military confrontations between Afghanistan and Pakistan. According to The Guardian, the war has overshadowed the executions of political prisoners in Iran, including those involved in the mass protests of January 2026, allowing Iran to continue carrying out death sentences and other severe punishments with little international scrutiny. According to several Iran-focused human rights groups, the rate of sentencing and executions by hanging surged amidst the war. The groups state that in most of these cases, executed prisoners did not receive due process.
== Sources == Cooper, Tom; Grandolini, Albert; Delalande, Arnaud (2015). Libyan Air Wars, Part 1: 1973-1985. Helion & Company Publishing. ISBN 978-1-909982-39-0. Cooper, Tom; Grandolini, Albert; Delalande, Arnaud (2016). Libyan Air Wars, Part 3: 1986-1989. Helion & Company Publishing. ISBN 978-1-910294-54-3. Cooper, Tom & Weinert, Peter (2010). African MiGs: Volume I: Angola to Ivory Coast. Harpia Publishing LLC. ISBN 978-0-9825539-5-4.
Sources: en.wikipedia.org
Dihexa is a synthetic peptide investigated in preclinical research. It is often classified as an angiotensin IV analog or an HGF mimetic. It is not an approved medicine.
No. Regulatory agencies have not approved dihexa for human use. It is sold as a research chemical in some markets, and human safety and efficacy data are lacking.
Laboratory studies have examined its effects on synapse formation and cognitive tasks in animals. These are early-stage findings. They do not prove benefits or safety in people.
Dihexa is a synthetic peptide derived from angiotensin IV and studied for effects on synaptic plasticity. It is often described as a hepatocyte growth factor mimetic. It is not an approved medication.